0001225208-22-006815.txt : 20220510 0001225208-22-006815.hdr.sgml : 20220510 20220510205438 ACCESSION NUMBER: 0001225208-22-006815 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220507 FILED AS OF DATE: 20220510 DATE AS OF CHANGE: 20220510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WANG HUIMIN CENTRAL INDEX KEY: 0001204553 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15525 FILM NUMBER: 22911784 MAIL ADDRESS: STREET 1: C/O EDWARDS LIFESCIENCES STREET 2: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edwards Lifesciences Corp CENTRAL INDEX KEY: 0001099800 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 364316614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 9492502500 MAIL ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP. DATE OF NAME CHANGE: 20090225 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP DATE OF NAME CHANGE: 20000203 FORMER COMPANY: FORMER CONFORMED NAME: CVG CONTROLLED INC DATE OF NAME CHANGE: 19991126 4 1 doc4.xml X0306 4 2022-05-07 0001099800 Edwards Lifesciences Corp EW 0001204553 WANG HUIMIN ONE EDWARDS WAY IRVINE CA 92614 1 CVP, Japan & Intercontinental Common Stock 2022-05-07 4 F 0 363.0000 100.5200 D 97553.8018 D Common Stock 2022-05-08 4 M 0 6956.0000 0 A 104509.8018 D Common Stock 2022-05-08 4 F 0 4210.0000 100.5200 D 100299.8018 D Common Stock 2022-05-09 4 M 0 3675.0000 35.1967 A 103974.8018 D Common Stock 2022-05-09 4 S 0 3675.0000 98.7100 D 100299.8018 D Performance Rights 2022-05-08 4 M 0 6956.0000 0.0000 D 2022-05-08 2026-05-07 Common Stock 6956.0000 0.0000 D Employee Stock Option (Right to Acquire) 35.1967 2022-05-09 4 M 0 3675.0000 0.0000 D 2016-06-12 2023-05-11 Common Stock 3675.0000 33075.0000 D On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2022. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Linda J. Park, Attorney-in-Fact 2022-05-10